2017N346371_00 CONFIDENTIA L
GlaxoSmithKline group of companies 206924
1TITLE PA GE
Protocol Title: An open -label study  to evaluate correct use and ease of use of the 
ELLIPTA D ry Powder Inhaler (DPI) in pediatric patients currentl y receiving inhaled 
therap y for treatment of their asthma
Protocol Number : 206924 
Short Title : An open -label study  to evaluate correct use and ease of use of the ELLIPTA 
DPI in pediatric patients with asthma
Compound Number: GSK2285997 
Sponsor Name and Legal Registered Address: 
GlaxoSmithKline Research & Development Limited
980 Great West Road
Bren tford
Middlesex, TW8 9GS
UK
Medical Monitor Name and Contact I nformation can be found in the Study  Reference 
Manual
Regulatory Agency Identifying Number(s): N/A
Approval Date: 23-JAN -2018
Copy right 2018 the GlaxoSmithKline group of companies.  Allrights reserved.   
Unauthori zed cop ying or use of this information is prohibited.
PPD
PPD
2017N346371_00 CONFIDENTIA L
206924
3TABLE OF CONTENTS
PAGE
1.SYNOPSIS ................................ ................................ ................................ ............... 6
2.SCHEDULE OF ACTIVITI ES (SOA) ................................ ................................ ......... 9
3.INTRODUCTION ................................ ................................ ................................ ....12
3.1. Study Rationale ................................ ................................ .......................... 12
3.2. Background ................................ ................................ ................................ 12
3.3. Benefit/Risk Assessment ................................ ................................ ............ 13
3.3.1. Risk Assessment ................................ ................................ ......... 14
3.3.2. Benefit Assessment ................................ ................................ .....15
3.3.3. Overall Benef it:Risk Conclusion ................................ ................... 15
4.OBJECTIVES AND ENDPO INTS ................................ ................................ ........... 15
5.STUDY DESIGN ................................ ................................ ................................ ....17
5.1. Overall Design ................................ ................................ ............................ 17
5.1.1. Visit 0 ................................ ................................ ........................... 18
5.1.2. Visit 1 ................................ ................................ ........................... 18
5.1.3. Visit 2 ................................ ................................ ........................... 19
5.2. Number of Participants ................................ ................................ ............... 19
5.3. Participant and Study Completion ................................ ............................... 19
5.4. Scientific Ratio nale for Study Design ................................ .......................... 20
5.5. Dose Justification ................................ ................................ ........................ 20
6.STUDY POPULATION ................................ ................................ ........................... 20
6.1. Inclusion Criteria ................................ ................................ ......................... 20
6.2. Exclusion Criteria ................................ ................................ ........................ 21
6.3. Lifestyle Restrictions ................................ ................................ ................... 22
6.3.1. Meals and Dietary Restrictions ................................ .................... 23
6.3.2. Activity ................................ ................................ ......................... 23
6.4. Screen Failures ................................ ................................ ........................... 23
7.TREATMENTS ................................ ................................ ................................ .......24
7.1. Treatments Administered ................................ ................................ ............ 24
7.2. Dose Modification ................................ ................................ ....................... 24
7.3. Method of Treatment Assignment ................................ ............................... 24
7.4. Blinding ................................ ................................ ................................ .......25
7.5. Preparation/Handling/Storage/Accountability ................................ .............. 25
7.6. Treatment Compliance ................................ ................................ ................ 26
7.7. Concomitant Therapy ................................ ................................ .................. 26
7.8. Treatment after the End o f the Study ................................ .......................... 26
8.DISCONTINUATION CRIT ERIA ................................ ................................ ............. 27
8.1. Discontinuation of Study Treatment ................................ ............................ 27
8.1.1. Liver Chemistry Stopping Criteria ................................ ................ 27
8.1.2. QTc Stopping Criteria ................................ ................................ ..27
8.1.3. Temporary Discontinuation ................................ .......................... 27
8.2. Withdrawal from the Study ................................ ................................ .......... 28
2017N346371_00 CONFIDENTIA L
206924
48.3. Lost to Follow Up ................................ ................................ ........................ 28
9.STUDY AS SESSMENTS AND PROCED URES ................................ ..................... 29
9.1. Assessments ................................ ................................ .............................. 29
9.1.1. Screening and Critical Baseline Assessments ............................. 29
9.1.1.1. Visit 1 ................................ ................................ ......... 29
9.1.1.1.1. Training and correct use 
Assessments ................................ .......... 29
9.1.2. V2 Assessments ................................ ................................ .......... 30
9.1.2.1. Ease of use Questionnaire ................................ ......... 30
9.1.2.2. Correct Use ................................ ................................ 30
9.2. Adverse Events ................................ ................................ ........................... 31
9.2.1. Time Period and Frequency for Collecting AE and SAE 
Information ................................ ................................ ................... 31
9.2.2. Method of Detecting AEs and SAEs ................................ ............. 32
9.2.3. Follow -up of AEs and SAEs ................................ ......................... 32
9.2.4. Regulatory Reporting Requirements for SAEs ............................. 32
9.2.5. Death Events ................................ ................................ ............... 32
9.2.6. Asthma Exacerbation ................................ ................................ ...33
9.3. Treatment of Overdose ................................ ................................ ............... 33
9.4. Safety Assessments ................................ ................................ ................... 33
9.4.1. Physical Examinations ................................ ................................ .34
9.4.2. Vital Signs ................................ ................................ .................... 34
9.4.3. Electrocardiograms ................................ ................................ ......34
9.4.4. Clinical Safety Laboratory Assessments ................................ ......34
9.4.5. Suicidal Risk Monitoring ................................ ............................... 34
9.5. Pharmacokinetics ................................ ................................ ....................... 34
9.6. Pharmacodynamics ................................ ................................ .................... 34
9.7. Genetics ................................ ................................ ................................ .....34
9.8. Biomarkers ................................ ................................ ................................ .34
9.9. Health Economics OR Medical Resource Utilization and Health 
Economics ................................ ................................ ................................ ..34
10.STATISTICAL CONSIDER ATIONS ................................ ................................ ........ 35
10.1. Hypothesis ................................ ................................ ................................ ..35
10.2. Sample Size Determination ................................ ................................ ........ 35
10.2.1. Sample Size Assumptions ................................ ........................... 35
10.2.2. Sample Size Sensitivity ................................ ................................ 35
10.3. Populations for Analyses ................................ ................................ ............ 36
10.4. Statistical Analyses ................................ ................................ ..................... 36
10.4.1. Efficacy Analyses ................................ ................................ ......... 37
10.4.2. Safety Analyses ................................ ................................ ........... 37
10.4.3. Other A nalyses ................................ ................................ ............ 38
10.4.4. Interim Analyses ................................ ................................ .......... 38
11.REFERENCES ................................ ................................ ................................ .......39
12.APPENDICES ................................ ................................ ................................ ........ 41
12.1. Appendix 1: Abbreviations and Trademarks ................................ ................ 41
12.2. Appendix 2: Study Governance Considerations ................................ .......... 42
12.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ................................ .......46
2017N346371_00 CONFIDENTIA L
206924
512.4. Appendix 4: Country -specific requirements ................................ ................. 51
12.5. Appendix 5: ELLIPTA DPI correct use and critical error checklist ............... 52
12.5.1. Checklist ................................ ................................ ...................... 52
12.6. Appendix 6: Ease of us e Questionnaire(s) ................................ .................. 54
12.6.1. Ease of use Questionnaire (Participant Stratum 1, ages 5 -
7 years) ................................ ................................ ....................... 54
12.6.1.1. Version A ................................ ................................ ....54
12.6.1.2. Version B ................................ ................................ ....54
12.6.2. Ease of use Questionnaire (Participant Stratum 2, ages 8 -
11 years) ................................ ................................ ...................... 54
12.6.2.1. Version A ................................ ................................ ....55
12.6.2.2. Version B ................................ ................................ ....55
12.6.3. Ease of use Questionnaire (Parent/Guardian) ............................. 55
12.6.3.1. Version A ................................ ................................ ....55
12.6.3.2. Version B ................................ ................................ ....56
12.7. Appendix 7: Protocol Amendment History ................................ ................... 57
2017N346371_00 CONFIDENTIA L
206924
61. SYNOPSIS
Protocol Title: An open -label study  to evaluate correct use and ease of use of the 
ELLIPTA D ry Powder Inhaler in p ediatric patients currentl y receiving inhaled therap y 
for treatment of their asthma
Short Title: An open -label study  to evaluate correct use and ease of use of the ELLIPTA 
Inhaler in pediatric patients with asthma
Rationale:
The ELLIPTA Dry  Powder Inhaler (DPI) requires few steps, achieves consistent dosing 
and eliminates the hand -breath coordination required b y metered dose inhalers (MDIs).  
While muc h research has assessed various features, including ease of use, correct use, 
critical errors and participant preference of the ELLIPTA DPI  in an adult asthmatic 
population, there is very  little information regarding these features in the pediatric 
populat ion.
This study  has been designed to assess the correct use of the ELLIPTA DPIin pediatric 
participants with asthma.  I t will also assess the ease of use of the ELLIPTA DPI , as 
evaluated b y participants who have been deemed able to use the ELLIPTA DPI  correctly .
Objectives and Endpoints:
-Stratum 1: 5 to 7 y ears old at V0 (inclusive)
-Stratum 2: 8to 11 years old at V0 (inclusive)
Objectives Endpoints
Primary
To determine the proportion of participants 
from each stratum who demonstrate 
correct use of the E LLIPTA DPI after the 
study period at V2.The percentage of participants from each 
stratum who demonstrate correct use of the 
ELLIPTA DPI after the study period at V2.
To determine the proportion of participants 
from each stratum who rate the use of the 
ELLIPTA DPI as easy to use , from those 
who could demonstrate correct use of the 
ELLIPTA DPI after the study period at V2.The percentage of participants from each 
stratum who rate the ELLIPTA DPI as easy 
to use, from those who could demonstrate 
correct use o f the ELLIPTA DPI after the 
study period at V2.
Secondary
To determine the proportion of participants 
from each stratum who demonstrate 
correct use of the ELLIPTA DPI after initial 
training from healthcare professional (HCP) 
at V1 .The percentage of part icipants from each 
stratum who demonstrate correct use of the 
ELLIPTA DPI after initial training from HCP 
at V1 .
To determine the proportion of participants 
who demonstrate correct use of the 
ELLIPTA DPI after the study period at V2.The percentage of par ticipants who 
demonstrate correct use of the ELLIPTA DPI 
after the study period at V2 .
To determine the proportion of participants The percentage of participants who rate the 
2017N346371_00 CONFIDENTIA L
206924
7Objectives Endpoints
who rate the use of the ELLIPTA DPI as 
easy to use, from those who could 
demonstrate correct use of the ELLIPTA 
DPI after th e study period at V2.ELLIPTA DPI as easy to use, from those 
who could demonstrate correct use of the 
ELLIPTA DPI after the study period at V2.
To determine the proportion of participants 
who made at least one c ritical error during 
use of the ELLIPTA DPI after initial training 
from HCP at V1.The percentage of participants who made at 
least one critical error during use of the 
ELLIPTA DPI after initial training from HCP 
at V1 .
Overall Design:
This is a multi -center, single arm, stratified, open -label, randomized (version of the 
ELLIPTA DPI ease of use questionnaire) placebo study .  The stud y will involve up to 
3study  visits.  Participants will continue to use their prescribed asthma medications after 
meeting th e eligibility  criteria for the duration of the study .  The study  will consist of 
pediatric asthmatic patients and it will be stratified by  age (Stratum 1; 5 -7 years old 
inclusive and Stratum 2; 8 -11 years old inclusive).  Only  participants who are naïve to the 
ELLIPTA DPI, have a documented history  of symptoms consistent with a diagnosis of 
asthma and have been receiving inhaled therap y for treatment of their asthmatic 
symptoms for at least 3 months prior to V0 will be considered eligible.
V0 and V1 may  take place on the same day .  At V1, participants will be trained and 
demonstrate correct use of the ELLIPTA DPI.  If successful, they  will take the placebo 
ELLIPTA DPI home for the duration of the stud y period (28 ± 2 day s) and take one dose 
daily .  Upon retu rn to the study  clinic at V2, participants will complete the ease of use 
questionnaire to which they  have been randomized and then demonstrate correct use of 
the ELLIPTA DPI prior to any  re-training.  Compliance with once dail y usage of the 
ELLIPTA DPI dur ing the study  period will be recorded.
The protocol specific study  requirements will be reviewed with each participant and their 
parent/guardian.  Informed consent and the appropriate assent will be obtained from all 
who volunteer to take part in the study , prior to the initiation of the first study  procedure.
2017N346371_00 CONFIDENTIA L
206924
8
Number of Participant s:
Approximately  88 participants from Stratum 1 and 131 participants from Strat um2 will 
need to be screened . Assuming a withdrawal rate during the study  period of 3% , 
approxima tely 80participants from strata 1 and 12 0participants from strata 2 will 
complete the treatment period, return for V2 and be randomiz ed to aversion of ease of 
use questionnaire.
Treatment Groups and Duration:
The study  population will be stratified by  age (Stratum 1, 5 to 7 y ears old and Stratum 2, 
8to 11 years old) . The study  consists of up to 3 visits and a study  period of 28 ± 2 day s.  
Participants will be randomized to a version of the ease of use questionnaire in a 1:1 
allocation by  strata, as is defined below:
Randomization Group Ease of Use 
Questionnaire Version
Stratum 1 A
B
Stratum 2 A
B
There is no active treatment provided during this study  and participants will continue to 
take their own prescribed asthma medication for the duration o f the stud y.
2017N346371_00 CONFIDENTIA L
206924
92. SCHEDULE OF ACTIVITI ES (SOA )
The schedule of activities ( SoA) in Table 1details the timing of procedures / assessments 
to be performed in this study .
Any changes in the timing or addition of time points for any  plann ed stud y assessments 
must be documented and approved b y the relevant study  team member and then archived 
in the sponsor and site study  files, but will not constitute a protocol amendment. The 
institutional review boards (IRB)/independent ethics committee s(IEC)will be informed 
of an y safety issues that require alteration of the safety monitoring scheme or amendment 
of the informed consent form (ICF).
2017N346371_00 CONFIDENTIA L
206924
10Table 1 Schedule of A ctivities
ProcedureVisit 0 -
Screening 
(up to 30 
days befo re 
Day 1)Treatment Period
NotesVisit 1 (can 
occur on 
same day as 
screening)Early 
WithdrawalVisit 2
Day -30 0 28 ± 2All assessments concern study participants only, unless otherwise 
stated (parent/guardians).
Screening
Informed consent and asse nt XVisit 1 must occur within 30 days of signing of providing informed 
consent.  Must be signed before any study procedures.  Assent 
must be provided.
Inclusion and exclusion criteria XAll of the inclusion and none of the exclusion criteria must b e met 
prior to inclusion at V0. This includes ability to demonstrate correct 
use of the ELLIPTA DPI after training.
Demography X Age, sex, race, ethnicity .
Physical Examination X Including height and weight, 
Concomitant medicationsXConcomi tant medications pertaining to the participant’s diagnosis 
of asthma collected (minimum previous 3 months).
Past and current medical conditions  X
Asthma HistoryXParticipant will have a medical history of symptoms consistent with 
a diagnosis of asthma. 
Exacerbation History X Asthma exacerbation history for the previous year will be collected.
Randomization X Randomization refers to the version of the questionnaire only.
Safety
AE review ========================== ===== Collected fro m Visit 1 until the completion of the final assessment 
at Visit 2.
SAE review ============= ======================== Collected from time of informed consent/assent until the completion 
of the final assessment at Visit 2.
Concomitant medication sreview ============ =========================  Review any changes in concomitant medications.
Asthma exacerbations ============ ========================= Asthma exacerbation information will be collected fo rthe duration 
of the study (see Section 9.2.6 )
Questionnaires and Assessments
2017N346371_00 CONFIDENTIA L
206924
11ProcedureVisit 0 -
Screening 
(up to 30 
days befo re 
Day 1)Treatment Period
NotesVisit 1 (can 
occur on 
same day as 
screening)Early 
WithdrawalVisit 2
First training in correct use of ELLIPTA DPI 
by HCP X Initial training by HCP
Correct use of ELLIPTA DPI after first 
instruction by HCPX First demonstration of correct use of ELLIPTA DPI.
Seco nd and third training in correct use of 
ELLIPTA DPI by HCPX Training only if necessary (participant made errors)
Correct use of ELLIPTA DPI after second 
and third instruction by HCPX Second and third demonstrations of correct use of ELLIPTA DPI
Fourth and fifth training in correct use of 
ELLIPTA DPI by HCP and parent/guardianX Training only if necessary (participant made errors)
Correct use of ELLIPTA DPI after fourth 
and fifth instruction by HCP and 
parent/guardianXFourth and fifth demo nstrations of correct use of ELLIPTA DPI. 
After which time they will be registered as a screen failure if correct 
use has not been demonstrated.
Ease of use Questionnaire completion XThis is completed upon return to the site after the study period. 
This must occur before any other assessments at V2.
Compliance with ELLIPTA DPI X X This will be taken from the dose counter .
Correct use of ELLIPTA DPI after treatment 
periodXDemonstration of correct use of ELLIPTA DPI without any 
instruction at V 2.
Correct use of ELLIPTA DPI with 
instruction from parent/guardian XDemonstration of correct use of ELLIPTA DPI with instruction from 
parent/guardian at V2. Only necessary if correct use is not 
demonstrated during first attempt.
Placebo ELLIPTA DP I
Dispense Placebo ELLIPTA DPI(s) XProcedures for dispensation and return of clinical supplies will be 
described in detail in the Study Reference Manual (SRM).  If a 
participant completes all study requirements, they will need 2 
ELLIPTA DPIs.  One wil l remain at site and the other will be used 
during the study period.Return Placebo ELLIPTA DPI X X X
AE –Adverse Event, DPI -Dry Powder Inhaler , HCP -Healthcare Professional , SAE -Serious Adverse Events , 
2017N346371_00 CONFIDENTIA L
206924
123. INTRODUCTION
3.1. Stud y Rationale
The ELLIPTA Dry Powder Inhaler (DPI) requires few steps, achieves consistent dosing 
and eliminates the hand -breath coordination required b y metered dose inhalers (MDIs).  
While much research has assessed various features, including ease of use, correct use, 
critical errors (defined as an error that is likely  to signi ficantl yinhibit delivery  of the 
prescribed dose of medication to the patient) and patient preference of the ELLIPTA DPI 
in an adult asthmatic population, there is very  little information regarding these f eatures 
in the pediatric population [GlaxoSmithKline Document Number 2015N230821_00 ; 
GlaxoSmithKline Document Number 2017N314003_00 ; GlaxoSmithKline Document 
Number 2016N269989_01 ; Van der Palen , 2016 a; Van der Palen , 2016 b; Van der Palen , 
2016 c].  Previous studies in the pediatric population have shown that rates of correct use 
of inhalers is low,and even after instruction, patients still demonstrate poor inhalation 
technique when using a variet y of Dr y powder and Metered Dose Inhalers (MDI) 
[Kamps , 2000 a; Kamps , 2002 b].  Therefore, an inhaler that overcomes such barriers may  
beof high clinical relevance.
Accordingl y, this study  has been designed to assess the correct use of the ELLIPTA DPI
in pediatric participants with asthma.  I t will also assess the ease of use of the ELLIPTA 
DPI, as evaluated b y participants who have been deemed able to use the ELLIPTA DPI  
correctly .Recent work carried out by  the GSK has helped guide the development of 
meaningful questionnaires for use within this study . The primary  outcomes of this work 
illustr ated that binary  response options (eas y and hard) were more meaningful in this 
population. Furthermore, it helped guide the method of delivery , in that, the 5 -7 year old 
strata would need assistance when c ompleting the questionnaire, unlike the 8 -11 year old 
strata, who would be able to self -complete the questionnaire [NCT0331557 2, 2018 ].
3.2. Background
Asthma is a chronic inflammatory  disease of the airway s and lungs that results in 
hyperreactivity  and clinically  relevant e pisodes of wheezing.  The global prevalence of 
asthma is on the rise.  As of 2015, 358 million people globall y suffer from asthma and it 
is one of the leading causes of disability  in children between 5 and 11 y ears of age [GBD
2015 , 2016 ].It is most commonly  treated with Inhaled Corticosteroids (ICS) alone or in 
combination with a long actin g β2adrenergic agonist (L ABA) [GINA, 2017 ].
Instances of problematic asthma cases in the pediatric population have been attributed to
either ;misdiagnosis, environment alfactors and/or adherence to medication prescription
[Bush , 2015] .  The failure of a patient to adhere to their medication includes the inability  
to use their inhalation device correctl y and subsequentl y receive their prescribed dose, the 
impact of which depends primarily  upon the se verity  of the condition [Burgess , 2011 ].
Interventions to address issues related to adherence in pediatric populations have had 
limited success, with the most effective containing both educational and behavioral 
aspects [Morton , 2014] .
2017N346371_00 CONFIDENTIA L
206924
13Consequently , the ability of pediatric asthmatic patients to achieve and maintain correct 
use over time, which is defined as use of the inhaler in the manner described in the 
Instructions for Use (IFU) is becoming increa singly  recognized.
The choice of inhalation device is an important decision when considering treatment for 
asthma in this age group.  This has been illustrated in a recent study  of 8-16 year-old 
asthmatic patients, where only  8% could use their MDI  correct ly, while 16% 
(Turbuhaler) and 22% (Diskus) were able to use their DPI correctl y [Sleath , 2011].
Furthermore, inadequate technique reduces the effects of inhalation, thus a device that is 
easy to use and delivers drug to the l ungs effectively  is important. 
In order to combat such educational and behavioral barriers, the ELLIPTA DPI  has been 
designed to be simple for patients to use based on the number of steps required to use it 
correctly  and the amount of time required to be trained in correct use.  Previous studies in 
other populations have shown that the number of errors made while using the ELLIPTA 
DPI and the amount of time required to train users are reduced [Van der Palen , 2016 a;
Van der Palen , 2016 b; Van der Palen , 2016 c].  Therefore, the ELLIPTA DPI  has the 
potential to address some of the limitations regarding the correct use of other inhalers in 
the pediatric asthmatic population [Kamps , 2002 b].
Ultimately , the prescription and subsequent use of eas y to use DPIs is paramount and 
could be of high clinical value for the treatment and management of asthma in this 
population.  This study  is designed to as sess the correct use and ease of use of the 
ELLIPTA DPI b y pediatric participants with asthma, a population yet to be studied for 
their use of the ELLIPTA DPI .
3.3. Benefit/Risk A ssessment
This study  involves use of placebo ELLIPTA DPI, which does not contain any active 
treatment.  Participants will continue to take their own prescribed asthma medication and 
other concomitant medication for the duration of the study .
The placebo ELLIPTA DPI  contain sthe excipients lactose blended with magnesium 
stearate. Excipi ents of the study  inhaler are noted in Section 7.1. Participants with a 
known hy persensitivity  to any  of these or severe milk protein allergy  that could 
contraindicate stud y participation are excluded from the study  (Section 6). Participants
who meet the inclusion/exclusion criteria will continue their asthma treatment as 
prescribed b y their healthcare provider during their participation in the study. 
Participants should continue to follow up with their regular ph ysician for their asthma
healthcare during the study .
2017N346371_00 CONFIDENTIA L
206924
143.3.1. Risk A ssessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP)
Paradoxical bronchospasm, which may occur
with an immediate increase in wheezing after 
inhalation.As with other inhalation therapy, paradoxical 
bronchospasm may occur with an immediate 
increase in wheezing after dosing.  From post -
marketing data, paradoxical bronchospasm has 
been reported at a f requency of <1/10,000, 
including isolated reports [ Nicklas , 1990].This should be treated immediately with a fast 
and short acting inhaled bronchodilator.
Investigators will be instructed to assess the 
subject’ s condition to determine their eligibility to 
continue in the study and the need for alternative 
therapy.
Allergic reaction due to hypersensitivity to 
placebo excipients.The placebo inhalers contain the excipients 
lactose and lactose blended with magnes ium 
stearate. There are known allergies to these 
ingredients.Participant s with a known hypersensitivity to any 
of these, or severe milk protein allergy that could 
contraindicate study participation are excluded 
from the study (Section 6). If an allergic reaction 
occurs, it should be treated immediately with a 
fast and short acting inhaled bronchodilator. 
Investigators will be instructed to assess the 
subject’s condition to determine their eligibility to 
conti nue in the study and the need for alternative 
therapy.
2017N346371_00 CONFIDENTIA L
206924
153.3.2. Benefit A ssessment
As this is a placebo only  study , no direct benefit to the participant is expected as a result 
of taking part in the study.  No active treatment will be provided during the study . All 
participants will continue to receive their own asthma therap y as prescribed for the 
duration of the study . 
3.3.3. Overall Benefit:Risk Conclusion
The overall potential risk identified is minimal, due to the nature of the study.
4. OBJECTIVES A ND ENDPO INTS
Thestudy  will evaluate different aspects of correct use and ease of use of the ELLIPTA 
DPI in pediatric patients with asthma. The population will be stratified into two different 
age groups and will be referred to as Stratum 1 and Stratum 2 throughout this p rotocol.
-Stratum 1: 5 to 7 y ears old at V0 (inclusive)
-Stratum 2: 8to 11 years old at V0 (inclusive)
Objectives Endpoints
Primary
To determine the proportion of participants 
from each stratum who demonstrate 
correct use of the ELLIPTA DPI after the 
study period at V2.The percentage of participants from each 
stratum who demonstrate correct use of the 
ELLIPTA DPI after the study period at V2.
To determine the proportion of participants 
from each stratum who rate the use of the 
ELLIPTA DPI as easy to use ,from those 
who could demonstrate correct use of the 
ELLIPTA DPI after the study period at V2.The percentage of participants from each 
stratum who rate the ELLIPTA DPI as easy 
to use, from those who could demonstrate 
correct use of the ELLIPTA DPI after the 
study period at V2.
Secondary
To determine the proportion of participants 
from each stratum who demonstrate 
correct use of the ELLIPTA DPI after initial 
training from HCP at V1 .The percentage of participants from each 
stratum who demonstrate correct use of the 
ELLIPTA DPI after initial training from HCP 
at V1 .
To determine the proportion of participants 
who demonstrate correct use of the 
ELLIPTA DPI after the study period at V2.The percentage of participants who 
demonstrate correct use of the ELLIPT A DPI 
after the study period at V2 .
To determine the proportion of participants 
who rate the use of the ELLIPTA DPI as 
easy to use, from those who could 
demonstrate correct use of the ELLIPTA 
DPI after the study period at V2.The percentage of participant s who rate the 
ELLIPTA DPI as easy to use, from those 
who could demonstrate correct use of the 
ELLIPTA DPI after the study period at V2.
To determine the proportion of participants 
from each stratum who made at least one 
critical error during use of the E LLIPTA DPI 
after initial training from HCP at V1.The percentage of participants from each 
stratum who made at least one critical error 
during use of the ELLIPTA DPI after initial 
training from HCP at V1 .
2017N346371_00 CONFIDENTIA L
206924
16Objectives Endpoints
Exploratory
To determine the proportion of partic ipants
from each stratum who rate the ability to 
tell how many puffs are left in the ELLIPTA 
DPIas easy after the study period at V2 .The percentage of participants from each 
stratum who rate the ability to tell how many 
puffs are left in the ELLIPTA DPIas easy 
after the study period at V2.
To determine the proportion of participant’s 
parents/guardians who rate the ability to 
tell how many doses are remaining in the 
ELLIPTA DPI as easy or very easy after 
the study period at V2 .The percentage of particip ant’s 
parents/guardians who rate the ability to tell 
how many doses are remaining in the 
ELLIPTA DPI as easy or very easy after the 
study period at V2 .
To determine the proportion of participant’s 
parents/guardians who would be ‘likely ’or 
‘very likely ’to ask their doctor for the 
ELLIPTA DPI if the participants current 
daily inhaled medication(s) were available 
in the ELLIPTA DPIafter the study period 
at V2 .The percentage of participant’s 
parents/guardians who would be likely or 
very likely to ask their doctor for the 
ELLIPTA DPI if the participants current daily 
inhaled medication(s) were available in the 
ELLIPTA DPIafter the study period at V2 .
To determine the proportion of participants 
from each stratum who c andemonstrate 
correct use after the stu dy period at V2
with assistance from parents/guardians.The percentage of participant s from each 
stratum who demonstrated correct use after 
the study period at V2 with assistance from 
parents/guardians.
To determine the proportion of participants 
from eac h stratum who made at least one 
critical error during use of the ELLIPTA DPI 
after the study period at V2 .The percentage of participants from each 
stratum who made at least one critical error 
during use of the ELLIPTA DPI after the 
study period at V2 .
Todetermine the proportion of participants 
who made at least one critical error during 
use of the ELLIPTA DPI after initial training 
from HCP at V1.The percentage of participants who made at 
least one critical error during use of the 
ELLIPTA DPI after initial training from HCP 
at V1 .
2017N346371_00 CONFIDENTIA L
206924
175. STUDY DESIGN
5.1. Overall Design
Figure 1 Study  Schematic

2017N346371_00 CONFIDENTIA L
206924
18This is a multi -center, single arm, stratified, open -label, randomized (version of the 
ELLIPTA DPI ease of use questionnaire) placebo -only study.  The stud y will involve up 
to 3 study  visits.  Participants will continue to use their prescribed asthma medications 
after meeting the eligibility  criteria for the duration of the study .  Further information 
regarding the assessments that will occur at each visit will be locate in the Study  
Reference Manual (SRM).
5.1.1. Visit 0
Visit 0 (V0) and Visit 1 (V1) can occur on the same day .  Participants between 5 and 11 
years old (inclusive) at V0, who are naive to the ELLIPTA DPI (with no previous 
treatment experie nce with any  medication administered bythe ELLIPTA DPI), have a 
documented history  of symptoms consistent with a diagnosis of asthma and are currentl y 
receiving maintenance and/or rescue therap y for asthma treatment, will be considered 
eligible to partici pate in the study .
At V0, written informed consent will be obtained from eligible participant’s 
parent/guardian and the respective assent, along with medical history , demography  and 
current asthma therap y.  Participants will also be stratified b y age into one of two strata:
-Stratum 1: 5 to 7 y ears old at V0 (inclusive)
-Stratum 2: 8to 11 years old at V0 (inclusive)
5.1.2. Visit 1
At V1, all participants will be trained in correct use of the ELLIPTA DPI by  a Healthcare 
Professional (HCP) as would occur in general p ractice.  Participants will then be asked to 
attempt to use the ELLIPTA DPI , without guidance from either the HCP or their 
parent/guardian.  Should the study  participant be unable to use the ELLIPTA DPI  
correctly , the HCP will be allowed to instruct the pa rticipant two more times.  After each 
round of instruction, the participant will attempt to correctly  use the ELLIPTA DPI .  If 
the study  participant is still unable to demonstrate correct use of the ELLIPTA DPI  after 
all three instructions b y the HCP, the parent/guardian of the participant will be able to 
assist in the instruction of correct use of the ELLIPTA DPI  for another two attempts.  I t is 
therefore important that the parent/guardian is engaged with the HCP during delivery  of 
the instructions on corr ect use.  If the participant still cannot demonstrate correct use after 
all five attempts, they  will be registered as a screen failure.  All participants who can 
demonstrate correct use at any  stage in this process will be informed of their correct use 
andwill perform no further demonstrations at this visit.  
Participants will then take a placebo ELLIPTA DPI  home for the duration of the study  
period (28 (±2) day s).  Participants will be instructed to take one inhalation from the 
ELLIPTA DPI as would be pr escribed (once dail y) at approximately the same time every  
day.  Participant’s parent/guardian will need to make note of the date and time of each 
dose administered of the ELLIPTA DPI on the worksheet provided.  This worksheet can 
also be used to make note of an y adverse or serious adverse events (AEs/SAEs) that 
occur during the stud y period.  Participant’s parents/guardians must contact the 
investigative site if the participant experiences any clinical worsening of their asthma. 
Further information on this procedure is located in Section 9.1.1 .
2017N346371_00 CONFIDENTIA L
206924
195.1.3. Visit 2
Participants will return to the site for V2 after the study  period, and will be randomized 
(1:1 allocation) to determine the version of the ease of use questionnaire they will rec eive 
(Version A orVersion B) located in Appendix 6 .  Prior to the correct use assessment, the 
participant will complete the version of the ease of use questionnaire according to their 
randomization allocation.  The participant’s pare nt/guardian will then complete a 
questionnaire to assess various features of the ELLIPTA DPI  (Appendix 6 ) according to 
the same randomization allocation as their dependent.
After completion of the ELLIPTA questionnaire(s), the partici pant’s ability  to correctly  
use the ELLIPTA DPI will be assessed.  At this visit during attempt 1, there will be no 
instruction, coaching, comment or direction given by  the HCP or parent/guardian.  Onl y 
one attempt to correctly  use the inhaler will be cond ucted during this assessment.  I f the 
participant is unable to demonstrate correct use in their first attempt at this visit, they  will 
have another attempt, in which, they  will receive assistance from their parent/guardian.
At this visit, the number of dos es administered b y the participant during the study  period 
will be noted and participants will be discharged from the study .
5.2. Number of Participants
Approximately  219 participants between 5 and 11 y ears old (inclusive) with a 
documented history  of symptoms consistent with a diagnosis of asthma (88 participants 
from Strat um1 and 131 participants from Strat um2)will need to be screened to achieve 
83participants from strat um1 and 1 24participants from strat um2 who meet the 
eligibility  criteria at V1 , assum ing a 5% failure rate of being able to correctly  use the 
ELLIPTA DPI at V1 .  Further participants may  be screened to ensure that at least 83 
participants from strata 1 and 124 participants from strata 2 enter the study period.
Assuming a withdrawal rate during the treatment period of 3% , approximately  80
participants from strata 1 and 12 0participants from strata 2 will complete the treatment 
period, return for V2 and be randomiz ed to aversion of ease of use questionnaire. Based 
on the assumption that 80% of participants from both strata will be able to demonstrate 
correct use of the ELLIPTA DPI at V2 . it is expected that 6 4participants from stratum 1 
and 96 participants from stratum 2 will be included in the anal ysis of the second primary  
endpoint regard ing ‘ease of use’. 
5.3. Participant and Study  Completion
A participant is considered to have completed the study  if he/she has completed all 
phases of the stud y including the last scheduled procedure shown in the SoA (Section 2).
The end of the stud y is defined as the date of the last visit of the last participant in the 
study .
2017N346371_00 CONFIDENTIA L
206924
205.4. Scientific Rationale for Study  Design
Participants are required to be naïve to (have no previous experience with) the ELLIPTA 
DPI in order to appropriately  assess their ability  to be trained in, demonstrate correct use 
and assess its ease of use.  
Stratification by  age of the participants involved in the study  was chosen in order to 
appropriatel y account for the potential differences in cognitive ability  with respect to the 
ease of use questionnaires.  This enables anal ysis of these two strata separately  for this 
study  and allows for the variation in delivery  of the questionnaires distributed .  Previous 
questionnaires have been modified for suitability  in this pediatric population. The 
development of these questionnaires and suggestions for their delivery has been informed 
by earlier work conducted by  the Value Evidence Outcomes team with GSK
[NCT0331557 2, 2018 ].  
Inactive t reatment was chosen as it avoids the potential bias related to the possible 
clinical improvement of the participant’s attitudes and perceptions on the ease of use of 
the DPI  an inactive treatment was chosen.  Furthermore, adding a placebo ELLIPTA DPI 
to the participants existing asthma therap y avoids the need for wash -in/out periods and 
the need to discontinue current asthma medications for study  visits.
The requirement for two study  visits excluding screening is to assess the ability  of the 
participant to be taught, retain that teaching /training and carry  out a correct use 
demonstration.  I t will also determine if the ability  of a pediatric participant to correctl y 
use their inhaler diminishes or is lost over time after input from the participant’s 
parent/g uardian only .  The time between visits of 4 weeks was chosen as this is deemed 
long enough to lose the ability  to correctly  use an inhaler and to accuratel y assess the ease 
of use of the ELLIPTA DPI . It also has been the time frame used in previous correc t use 
studies in other populations [GlaxoSmithKline Document Number 2017N314003_00 ; 
GlaxoSmithKline Document Number 2016N269989_01 ].  Furthermore, this treatment 
period (approximately  one month) resembles t he timing of inhaler refill and potential 
education at a pharmacy  or by  a HCP.
5.5. Dose Justification
This is not applicable as this is a placebo -only study.
6. STUDY POPULA TION
Prospective approval of protocol deviations to recruitment and enrolment criteria, al so 
known as protocol waivers or exemptions, is not permitted.
6.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria 
apply :
2017N346371_00 CONFIDENTIA L
206924
21Age
1.Participant s between 5 and 11 y ears old (inclusive) , at the time of theV0.
Type of Participant and Disease Characteristics
2.Participants with a documented history  of symptoms consistent with a diagnosis of 
asthma for at least 6 months prior to V0 (includes asthma diagnosis).
Sex
3.Male sand premenarchial female s.
Informed Conse nt
4.Written informed consent from at least one parent/ guardian and the accompany ing 
informed assent from the participant (where the participant is able to provide assent) 
prior to admission to the study .
a.If applicable, the participant must be able and willi ng to give assent to take 
part in the study  according to the local requirement. The study  
investigator is accountable for determining a child's capacit y to assent to 
participation in a research study , taking into consideration an y standards 
set by  the res ponsible IEC/I RB.
5.Participant and their legal guardian understand and are willing, able, and likely  to 
comply  with study  procedures and assessments .
Current Asthma Therapy
6.Participan t must have beenreceiving asthma treatment (rescue or maintenance) for 3 
months prior to entry  onto the study .
7.Participant must have never been trained in correct use of, or used the ELLIPTA 
DPI previously .
Study Procedures
8.Participants must be able to demonstrate correct use of the ELLIPTA DPI  after 
coaching/training at V1.
9.Participan tsmust be able to converse and understand verbal instruction in English. 
6.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions
1.Concurrent diagnosis of other respiratory  disorders including active tuberculosis, 
lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary  hypertension, 
interstitial lung diseases , cystic fibrosis or other active pulmonary  diseases.
2.Concurrent diagnosis of psy chiatric or ps ychological or an y other disorders that in 
the opinion of the investigator may  affect the ability  of the participant to comply  
with study  procedures or requirements.
2017N346371_00 CONFIDENTIA L
206924
22Asthma exacerbation history:
3.Has experienced anexacerbation which required oral/sy stemic corticosteroids in the 
three months prior to V0.
4.Has been hospitalized for an episode of asthma within three months of V0.
5.Has had an asthmatic episode requiring intubation, associated with h ypercapnea, 
respiratory  arrest or hy poxic seizures.
Contraindications: 
6.Has exhibited sy mptoms of a recent acute respiratory  tract infection within one week 
of V0.
7.History  of hypersensitivity  to any  components of the study  inhaler s(e.g., lactose, 
magnesium stearate). In addition, participan ts with a history  of severe milk protein 
allergy  that, in the opinion of the study  physician, contraindicates participation will 
also be excluded.
8.Historical or current evidence of clinicall y significant or rapidl y progressing or 
unstable cardiovascular, neurological, renal, hepatic, immunological, endocrine
(including diabetes or thy roid disease) or h ematological abnormalities that are 
uncontrolled. Significant is defined as an y disease that, in the opinion of the 
investigator, would put the safet y of the participant at risk through participation, or 
which would affect the analy sis if the disease/condition exacerbated during the 
study .
Diagnostic assessments and other criteria
9.Parent or Guardian with a history  of psy chiatric disease, intellectual deficiency , 
substance abuse or other condition (e.g. inabilit y toread, comprehend or write) 
which may  affect:
Validity  of consent to participate in the study .
Adequate supervision of the participan t during the study .
Compliance of participan t with study  medication and study  procedures
Participant safet y and well -being.
10.Participants who have received an investigational drug and/or medical device within 
30 day s of e ntry into this study  (Screening ), or within five drug half -lives of the 
investigational drug, whichever is longer .
11.A participant will not be eligible for t his study  if he/she is an immediate family  
member of the participating investigator, sub -investigator, study  coordinator, or 
employ ee of the participating investigator.
6.3. Lifest yle Restrictions
There are no lifesty le restrictions.
2017N346371_00 CONFIDENTIA L
206924
236.3.1. Meals and Dietary  Restricti ons
There are no meals or dietary  restrictions.
6.3.2. Activity
There are no restrictions on activity .
6.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  
but do not subsequently  enter the 28-day treatment period.  This includes any  participant 
who is not able to demonstrate correct use of the ELLIPTA DPI at V1.  A minimal set of 
screen failure information is required to ensure transparent reporting of screen failure 
participants to meet the Consolidated Sta ndards of Reporting Trials (CONSORT) 
publishing requirements and to respond to queries from regulatory authorities. Minimal 
information includes demograph y, screen failure details, eligibility  criteria, and any  
SAEs.
Individuals who do not meet the criter ia for participation in this study  (screen failure) 
may be rescreened once. Rescreened participants should be assigned a new participant 
number. Participants are not eligible for rescreening if they  attended V1 and were 
instructed and/or assessed for their correct use of the ELLIPTA DPI in an y way.
2017N346371_00 CONFIDENTIA L
206924
247. TREATMENTS
Study  treatment is defined as an y investigational treatment(s), marketed product(s), 
placebo ,or medical device (s)intended to be administered to a study  participant according 
to the study  protocol.
Participants will need 2 placebo ELLIPTA DPIs during the study . One of which will be 
used at the site for assessments and will remain at site during the study  period.  The other 
placebo ELLIPTA DPI will be taken home by  the participant and will be used as di rected 
for the duration of the study  period. 
7.1. Treatments A dministered
Study Treatment Name: Placebo ELLIPTA DPI
Dosage formulation: Placebo DPI with two strips and 30 blisters per strip.
First strip: lactose monohydrate
Second strip: lactose monohydrate b lended with magnesium 
stearate
Route of Administration Oral Inhalation
Dosing instructions: Once Daily
Packaging and Labe lling Placebo DPI will be provided in the appropriate container. Each 
container will be labelled as required per country requirem ent. 
Manufacturer GSK
Device NA
7.2. Dose Modification
This is not applicable as this is a placebo onl y study and t here will be no dose 
modification during this study .
7.3. Method of Treatment A ssignment
Participants will be as signed to the e ase of use question naire version ( Appendix 6 ) they  
receive in accordance with the randomi zation schedule devise dby clinical statistics. 
Participants will be randomi zed using an Interactive Web Response Sy stem (I WRS). The 
system will be used b y the inv estigator or designee to register andrandomi ze the 
participan t. It will assign the participant to one of two questionnaire versions (Version A 
or Version B), see Appendix 6 .
2017N346371_00 CONFIDENTIA L
206924
25Eligible subjects will be randomized to receive 1 of the f ollowing 2 possible 
questionnaire versions (1:1 allocation) at V2.  The variation between versions concerns 
the order of the response options provided to participants.  This reduces the response bias 
caused b y the ordering of the questionnaire responses (Appendix 6 ).  Parents/guardians 
will receive the same ordering of responses as their dependent.
Randomization Group Ease of Use 
Questionnaire Version
Stratum 1 A
B
Stratum 2 A
B
7.4. Blinding
This is an open -label study .  The partici pants and the investigator will be able to 
recognize the stud y inhaler that the participant is receiving.  The participant will be 
informed that the study  inhalers contain no active treatment.   However, the version of the 
ease of use questionnaire that wil l be answered b y a participant and their legal guardian 
will be assigned using an I WRS.  The site will use the IWRS prior to any  assessments by  
the participant at V2.  The site will record the randomization assignment on the 
applicable case report form, if required.  Potential response bias will be reduced by  
randomizing the ease of use questionnaire answered by  participants, which differ on the 
ordering of responses provided in each question. 
7.5. Preparation/Handling/Storage/A ccountability
-The investigator or designee must confirm appropriate temperature conditions 
have been maintained during transit for all study  treatment received and any  
discrepancies are reported and resolved before use of the study  treatment.   Details 
regarding transit and storage conditi ons for stud y treatments will be included in 
the SRM.
-Only  participants enrolled in the study  may  receive study  treatment and only  
authorized site staff may  supply  or administer study  treatment. All study  
treatments must be stored in a secure, environment ally controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions 
with access limited to the investigator and authorized site staff.
-The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study  treatment accountability , reconciliation, and 
record maintenance (i .e.receipt, reconciliation, and final disposition records).
-Further guidance and information for the final disposition of unused study  
treatment are provid ed in the SRM . 
2017N346371_00 CONFIDENTIA L
206924
26-Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safet y risks to site staff .  
-Material Safet y Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investigator, where this is required b y local laws, or is available upon request 
from GSK.
7.6. Treatment Compliance
When participants are dosed at the site, they  will receive study  treatment directl y from 
theinvestigator or designee, under medical supervision.  The date and time of each dose 
administered in the clinic will be recorded in the source documents.  The dose of study  
treatment and stud y participant identification will be confirmed at the time of do sing b y a 
member of the stud y site staff other than the person administering the stud y treatment.
When participants self -administer study  treatment at home, compliance with the 
ELLIPTA DPI dosing regimen will be assessed by  recording the number of ELLI PTA 
DPI doses dispensed by  each participant obtained by  reading the dose counter upon 
return of the participant at V 2.The participant’s parent/guardian will also receive a 
worksheet to note the date and time of each dose administered during the study  period.
This information must be maintained and reconciled with study  treatment and compliance 
records.  Compliance from the dose counter onl y will be entered will be recorded in the 
electronic case report form (eCRF ).
7.7. Concomitant Therapy
Any medication or vaccin e (including over -the-counter or prescription medicines, 
vitamins, and/or herbal supplements) that the participant is receiving at the time of 
enrolment or receives during the stud y must be recorded along with:
reason for use
dates of administration includ ing start and end dates
dosage information including dose and frequency
The Medical Monitor should be contacted if there are an y questions regarding 
concomitant or prior therapy .
7.8. Treatment after the End of the Study
There is no active treatment administere d during this study .  This is a placebo only  study  
and participants will not receive an y specific post -study  treatments.
2017N346371_00 CONFIDENTIA L
206924
278. DISCONTINUA TION CRIT ERIA
8.1. Discontinuation of Study  Treatment
Participants will be considered to have completed the study  upon completio n of all study  
procedures at V2 (final clinic visit).
The definition of an earl y withdrawal from the study will be an y participant who 
demonstrates correct use of the ELLIPTA DPI at V1, but is withdrawn or withdraws prior 
to completion of the V2 procedures .
A participant may  voluntarily  discontinue participation in the study  at an y time.  The 
investigator may  also, at his/her discretion; discontinue the participant from the study  at 
any time.  In addition, the investigator must make every  effort to have the participant 
return to the clinic as soon as possible after discontinuation of study  inhaler for an earl y 
withdrawal visit.  
The participant will be withdrawn from the stud y if any of the following criteria appl y:
The participant experience san asthma exa cerbation (see Section 9.2.6 ) that in the 
opinion of the investigator may  affect their ability to complete the requirements of 
the protocol.
The participant begins using a medication that is delivered b y the ELLIPTA DPI  
(exclud ing the stud y placebo ELLIPTA DPI).
After premature discontinuation from the study , the following evaluations and procedures 
should be completed at the earl y withdrawal visit and must be recorded in the eCRF as 
required.
Concomitant medication assessment
Adverse event assessment
Asthma exacerbation assessment
Collect used study  inhaler
Assess compliance with study  inhaler
8.1.1. Liver Chemistry Stopping Criteria
Not applicable as this is a placebo onl y stud y and there is not active treatment.
8.1.2. QTc Stopping Criteria
Not applicable as this is a placebo onl y stud y and there is not active treatment.
8.1.3. Temporary  Discontinuation
Participants who withdraw from the stud y treatment will not be able to continue in the 
study .
2017N346371_00 CONFIDENTIA L
206924
288.2. Withdrawal from the Study
A participant may  withdraw from the stud y at an y time at his/her own request, 
or may  be withdrawn at any  time at the discretion of the investigator for safety , 
behavio ural, compliance or administrative reasons.
If the participant withdraws consent for disclosure of future informatio n, the 
sponsor may  retain and continue to use any  data collected before such a 
withdrawal of consent.
Refer to the SoA (Section 2)for data to be collected at the time of study  
discontinuation and follow -up and for an y further evaluations that need to be 
completed.
8.3. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site. 
The following actions must be taken i f a participant fails to return to the clinic for a 
required stud y visit:
The site must attempt to contact the participant and reschedule the missed visit 
as soon as possible and counsel the participant on the importance of maintaining 
the assigned visit s chedule and ascertain whether or not the participant wishes to 
and/or should continue in the study .
Before a participant is deemed lost to follow up, the investigator or designee 
must make every  effort to regain contact with the participant (where possible , 3 
telephone calls and, if necessary , a certified letter to the participant’s last known 
mailing address or local equivalent methods). These contact attempts should be 
documented in the participant’s medical record.
Should the participant continue to be u nreachable, he/she will be considered to 
have withdrawn from the study  with a primary  reason of lost to follow -up.
2017N346371_00 CONFI DENTIA L
206924
299. STUDY A SSESSMENTS A ND PROCEDURES
Study  procedures and their timing are summarized in the SoA (Section 2).  Protocol 
waiver s or exemptions are not allowed.  Immediate safet y concerns should be discussed 
with the sponsor immediately  upon occurrence or awareness to determine if the 
participant should continue or discontinue study  treatment.   Adherence to the study  
design requirements, including those specified in the SoA (Section 2), is essential and 
required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibil ity criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable. 
Procedures conducted as part of the participan t’s routine clinic al management and 
obtained before signing of I CF may  be utilized for screening or baseline purposes 
provided the procedure met the protocol -specified criteria and was performed within the 
time frame defined in the SoA (Section 2).
9.1. Assessments
9.1.1. Screening and Critical Baseline A ssessments
The following will be recorded in the eCRF at V1:
9.1.1.1. Visit 1
9.1.1.1.1. Training and correct use Assessments
During V1, participants will be trained in the correct use of the ELLIPTA DPI  by the 
HCP.  The course of events during the training and assessments that occur at V1 is shown 
in Figure 2below.  During training, parental/guardian involvement is important, as they  
will have to assist in the training of the participant if the partic ipant is unable to 
demonstrate correct use after the first 3 attempts.
Figure 2 Training and assessments of correct use of ELLIPTA  DPI at V1

2017N346371_00 CONFI DENTIA L
206924
309.1.2. V2 A ssessments
After the 28 -day treatment period, participants will return for V2. Durin g this visit, the 
primary  assessments occur. Detail regarding the order of assessments at V2 is provided in 
Figure 3.
The following will be recorded in the eCRF at V2:
9.1.2.1. Ease of use Questionnaire
Prior to any  other assessments at V2 , participants will answer the ease of use 
questionnaire. The exact wording that will be used in this questionnaire and further 
instructions for administration of these questionnaires is located in Appendix 6 .  
For Stratum 1, the que stionnaire will be administered by  the interviewer. 
Responses will be provided according to the version to which the participant has 
been randomized.
For Stratum 2, the questionnaire will be self -administered. Responses will be 
provided according to the ve rsion to which the participant has been randomized.  
If the participant is unable to self -administer the questionnaire, then they  will be 
able to complete the questionnaire in the same manner as for stratum 1 
(interviewer administered).
Parents/Guardians w ill be assigned to the same version letter (A or B) of 
questionnaire to which their child/dependent was randomized.
9.1.2.2. Correct Use
At V2, participants will be assessed for their ability to demonstrate correct use of the 
ELLIPTA DPI.  There will be no training in correct use prior to the assessment.  There 
will also be no input from the participant’s parent/guardian during the first attempt at V2.  
If the participant is unable to demonstrate correct use at V2 after the initial attempt, the 
participant’s parent /guardian will be asked to instruct the participant in how to use the 
device correctly  before they  have their second attempt.
2017N346371_00 CONFI DENTIA L
206924
31Figure 3 Assessments regarding correct use and ease of use of the ELLIPTA  
DPI at V2
9.2. Adverse Events
The definitions of an AE or SAE can be found in Appendix 3.
The investigator and an y designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, considered related to the study  treatment or the study ,
or that caused the participant to discontinue the study  (see Section 8). 
9.2.1. Time Period and Frequency  for Collecting A E and SA E 
Information
All SAEs will be collected from the signing of the ICF until thetime point 
specified in the SoA (Section 2).
All AEs will be collected from the beginning of V1 until the timepoint specified 
in the SoA (Section 2).
Medical occurrences that begin before the start of study  treatment but after 
obtaining informed consent will be recorded on the Medical History /Current 
Medical Conditions section of the eCRF not the AE section.
All SAEs will be recorded and report ed to the sponsor or designee immediately  
and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor 
within 24 hours of it being available.
Inves tigators are not obligated to activel y seek AEs or SAEs in former study 
participants. However, if the investigator learns of any SAE, including a death, 
at an y time after a participant has been discharged from the study, and he/she 
considers the event to b e reasonabl y related to the study  treatment or study  
participation, the investigator must promptly  notify  the sponsor.
2017N346371_00 CONFI DENTIA L
206924
32The method of recording, evaluating, and assessing causality  of AEs and SAEs 
and the procedures for completing and transmitting SAE repor ts are provided in 
Appendix 3.
9.2.2. Method of Detecting A Es and SA Es
Care will be taken not to introduce bias when detecting AE and/or SAE. Open -ended and 
non-leading verbal questioning of the participant is the prefe rred method to inquire about 
AE occurrence. On the same worksheet that will be provided to note compliance (date 
and time) to their ELLIPTA DPI  regimen, the participant’s parent/guardian will be able 
to note any  AEs and SAEs that occur during the study  period.
9.2.3. Follow -up of A Esand SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All SAEs will be followed until the event is 
resolved, stabilized, otherwise explained, or the participant is los t to follow -up (as 
defined in Section 8.3). Further information on follow -up procedures is given in 
Appendix 3.
9.2.4. Regulatory  Reporting Requirements for SA Es
Prompt notification by  the investigator to the sp onsor of a SAE is essential so 
that legal obligations and ethical responsibilities towards the safet y of 
participants and the safety  of a study  treatment under clinical investigation are 
met. 
The sponsor has a legal responsibility  to notify  both the local regulatory  
authority  and other regulatory  agencies about the safet y of a stud y treatment 
under clinical investigation. The sponsor will comply  with country -specific 
regulatory  requirements relating to safet y reporting to the regulatory authority, 
Institu tional Review Boards (IRB)/Independent Ethics Committees (I EC), and 
investigators.
Investigator safety  reports must be prepared for suspected unexpected serious 
adverse reactions (SUSAR) according to local regulatory  requirements and 
sponsor policy  and for warded to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE or 
other specific safet y information ,e.g.summary  or listing of SAE) from the 
sponsor will review and then file it along with the Investigato r’s Brochure and 
will notify  the IRB/IEC, if appropriate according to local requirements.
9.2.5. Death Events
For all deaths, whether or not they  are considered SAEs, specific Death sections of the 
eCRF will be required to be completed. These sections include qu estions regarding 
cardiovascular (including sudden cardiac death) and non -cardiovascular death. 
2017N346371_00 CONFI DENTIA L
206924
33The Death eCRF is provided immediately  after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed wi thinone 
week of when the death is reported.
9.2.6. Asthma Exacerbation
An exacerbation is defined as deterioration of asthma requiring the use of sy stemic or 
oral corticosteroids (tablets, suspension, or injection) for at least 3 day s or a 
hospitalization or eme rgency department visit due to asthma that required systemic 
corticosteroids.
Subjects who experience an asthma exacerbation during the treatment period may  remain 
in the study  and should continue to use their placebo ELLIPTA DPI if possible. 
Treatment of asthma exacerbations with short term antibiotics (less than or equal to 14 
days) and s ystemic corticosteroids (less than or equal to 10 day s) is permitted.
For worsening asthma s ymptoms/exacerbations requiring: 
Emergency  treatment: the decision whether su ch a subject would continue in the 
study  or be withdrawn would be determined per investigator discretion. The Study  
Medical Monitor would be available to discuss any related questions with the 
investigator.
Hospitalization: such a subject should be withdra wn from the stud y 
Asthma exacerbations should not be recorded as an AE, unless they  meet the definition of 
a SAE and these SAEs will be recorded on the appropriate eCRF section and should be 
reported to GSK for all subjects. For the purposes of this stud y, asthma exacerbations 
will be collected and recorded on the asthma exacerbation log in the eCRF for all 
subjects. The time period for collection of asthma exacerbations on the asthma 
exacerbation log in the eCRF will begin from Visit 1 and will end when Visit 2/EW visit 
has been completed. 
Signs and s ymptoms of asthma included on the diary  cards will not be considered AEs 
and will not be recorded in the eCRF.
9.3. Treatment of Overdose
This study  only  contains placebo inhalers, with no active treatment. Ther efore, 
management of an overdose does not appl y.
9.4. Safet y Assessments
There are no mandated safet y assessments, other than monitoring for AEs and SAEs. 
This is described in detail in Section 9.2.
2017N346371_00 CONFI DENTIA L
206924
349.4.1. Physical Examinations
A phy sical examination will include, at a minimum, assessments of the 
Cardiovascular, Respiratory , Gastrointestinal and Neurological s ystems. Height 
and weight will also be measured and recorded.
Investigators should pay  special attention to clinical signs related to previous 
serious illnesses.
9.4.2. Vital Signs
This is not applicable as it is a placebo onl y study.
9.4.3. Electrocardiograms
This is not applicable as it is a placebo onl y study.
9.4.4. Clinical Safety  Laboratory  Assessments
This is not applicable as it is a placebo onl y study.
9.4.5. Suicidal Risk Monitoring
This is not applicable as it is a placebo onl y study.
9.5. Pharmacokinetics
Pharmacokinetic parameters are not evaluated in this study .
9.6. Pharmacody namics
Pharmacod ynamic parameters are not evaluated in this study
9.7. Genetics
Genetics a re not evaluated in this study .
9.8. Biomarkers
Biomarkers are not evaluated in this study .
9.9. Health Economics OR Medical Resource Utilization and 
Health Economics
Health Economics/Medical Resource Utilization and Health Economics parameters are 
not evaluated in this study .
2017N346371_00 CONFI DENTIA L
206924
3510. STATISTICA L CONSIDER ATIONS
10.1. Hypothesis
This is a descriptive, placebo only  study  and no formal inference is planned.  The two 
primary  objectives of the study  are:
To determine the proportion of participants from each stratum who demonstrate 
correct use of the ELLIPTA DPI after the study  period at V2
To determine the proportion of participants from each stratum who rate the use of 
the ELLIPTA DPI as easy to use , from those who could demonstrate correct use 
of the ELLIPTA DPI after the study  perio d at V2.
10.2. Sample Size Determination
10.2.1. Sample Size A ssumptions
The sample size calculation is based on the co -primary  endpoints, the percentage of 
subjects who demonstrate correct use of the ELLIPTA DPI  at V2, and the percentage of 
subjects who rate the use of the ELLIPTA DPI as eas y, among those who demonstrate 
correct use of the inhaler at V2. 
Approximately  219 subjects (i.e. 88 in stratum 1 and 131 in stratum 2) will be needed for 
screening in order to obtain 200 subjects (i.e. 80 in stratum 1 and 120 in st ratum 2) with 
available data to be randomized to an “ease of use” questionnaire, in anticipation of a 5% 
V0/V1 screen failure rate and then a 3% drop -out in the 4 -week interim period.
If the proportion of participants demonstrating correct use of the ELLIP TA DPI at V2 is 
80% for both strata 1 and 2, a total sample size of 80 participants in stratum 1 and 120 
participants in stratum2 will produce a confidence interval (CI) equal to the sample 
proportion ± 9. 28and ± 7.5 1percentage points .  In addition, giv en the assumption that 
the proportion of participants demonstrating correct use and evaluating the ELLIPTA 
DPIat V2 as eas y to use is 80%for both strata 1 and 2, a total sample size of 64 
participants in stratum 1 and 96 participants in stratum2 will pr oduce a CIequal to the 
sample proportion ± 10.42 and ± 8.44 percentage points . The sample size software used 
to estimate the precision and following sensitivity  anal ysis estimates is PASS version 12 
[Hintze , 2013].
10.2.2. Sample Si ze Sensitivity
With an assumed sample size, the difference between the h ypothesized and observed 
proportions of participants able to demonstrate correct use of the ELLIPTA DPI  at V2 
can affect the precision of the estimate.  If it is h ypothesized that the proportion of 
participants considered to be using the DPI  correctly  (observed proportion) is 80%, a 
sample size of 80 participants in stratum 1 could narrow the precision of the estimated 
proportion by  as little as ± 5.47% if the observed proportion is 95% , or widen the 
precision to as large as ± 11.18% if the observed proportion is 60%.  A sample size of 
120 participants in stratum 2 could narrow the precision of the estimated proportion by  as 
2017N346371_00 CONFI DENTIA L
206924
36little as ± 4.35% if the observed proportion is 95%, or widen t he precision to as large as ± 
9.09% if the observed proportion is 60%.
Also, the difference between the h ypothesized and observed proportions of participants 
rating the ease of use of the ELLIPTA DPI at V2 as eas y can also affect the precision of 
the estim ate.  If it is hy pothesized that the proportion of participants who can correctly  
use the ELLIPTA DPI correctl y is 80% and thus can rate the ELLIPTA DPI as eas y to 
use (observed proportion), a sample size of 64 participants in stratum 1 could narrow the 
precision of the estimated proportion by  as little as ± 6.21% if the observed proportion is 
95%, or widen the precision to as large as ± 12.53% if the observed proportion is 60%.  A 
sample size of 96 participants in stratum 2 could narrow the precision of th e estimated 
proportion by  as little as ± 4.93% if the observed proportion is 95%, or widen the 
precision to as large as ± 10.19% if the observed proportion is 60%.
10.3. Populations for A nalyses
For purposes of analy sis, the following populations are defined:
Population Description
Enrolled All participants who sign the ICF
Intent -to-Treat (ITT) The Intent -to-Treat (ITT) population is defined as all subjects who 
have been screened and received at least one dose of the study 
medication (placebo). This will cons titute the primary population for 
all study population and safety displays, and for some secondary 
and exploratory efficacy endpoint displays.
Modified Intent -to-Treat 
(MITT)The Modified Intent -to-Treat (MITT) population is defined as all 
subjects who ha ve been screened, received at least one dose of the 
study medication (placebo) and were randomized to a questionnaire 
at V2. This will constitute the primary population for the primary and 
most secondary efficacy endpoint displays.
10.4. Statistical A nalyses
Where possible, data from subjects who withdraw prematurely from the study  treatment
or the study  will be included in any  relevant anal yses. Specific details for inclusion will 
be detailed in the Reporting and Anal ysis Plan (RAP).
2017N346371_00 CONFI DENTIA L
206924
3710.4.1. Efficacy  Analyses
Endpoin t Statistical Analysis Methods
Primary The first primary analysis will calculate the proportion of subjects from each 
age stratum (5 to 7 years old (inclusive) and 8 to 11 years old (inclusive) who 
demonstrate correct use of the ELLIPTA DPI at V2. The pr oportion will be 
reported for both strata and calculated as those who demonstrate correct 
use at V2 / the number of participants whose use of the ELLIPTA DPI was 
evaluated at V2 .This will be reported along with a 95% CI for the proportion 
calculated usin g the exact binomial distribution.
The second primary analysis will calculate the proportion of subjects from 
each age stratum who rate the ELLIPTA DPI as ‘easy to use’, from those 
who demonstrated correct use of the ELLIPTA DPI at the end of the study 
period V2. The proportion will be reported for both strata and calculated as 
those who rate the ELLIPTA DPI as easy to use / those who demonstrate 
correct use of the ELLIPTA DPI at V 2. This proportion will be pre sented 
along with a 95% CI calculated using t he exact binomial distribution. 
Secondary The secondary endpoints will be reported in a similar fashion as the primary 
endpoints, with the proportion reported for each age stratum or collectively 
where necessary along with a 95% CI for the proportion cal culated using the 
exact binomial distribution.
Exploratory Will be described in the reporting and analysis plan
10.4.2. Safety  Analyses
All safet y anal yses will be performed on the Safety  Population. 
Endpoint Statistical Analysis Methods
SafetyNon-serious AE s, SAEs and AEs leading to study withdrawal will be collected.
Safety endpoints will include:
Incidence and type of serious adverse events
Incidence and type of non -serious adverse events
Incidence and type of non -serious AEs leading to study withdrawal
Incidence of Asthma Exacerbations
Incidence of Pneumonia
The incidence of any given adverse event is defined as the proportion of subjects 
who have experienced at least one such adverse event during the study period.
The number and percentage of subjects w ith SAEs, non -serious AEs and AEs 
leading to study withdrawal will be summarized by preferred term. 
2017N346371_00 CONFI DENTIA L
206924
3810.4.3. Other A nalyses
All other exploratory  endpoints will be detailed in the RAP.
10.4.4. Interim A nalyses
No interim anal yses are planned for this study .
2017N346371_00 CONFI DENTIA L
206924
3911. REFERENCES
Burgess S, Sly  P, Devadason S. Adherence with Preventive Medication in Childhood 
Asthma. Pulmonary Medicine. 2011.
Bush A, Fleming L. Diagnosis and management of asthma in children. BMJ. 
2015;350:h996.
GBD 2015 Disease and Injury  Incidence and Prevalence Col laborators. Global, regional, 
and national incidence, prevalence, and years lived with disability  for 310 disease and 
injuries, 1990 -2015: a systematic anal ysis for the Global Burden of Disease Study  2015. 
The Lancet. 2016;388:1545 -602. 
GINA , Global Init iative for Asthma. Global Strategy  for Asthma Management and 
Prevention. http://www.ginasthma.org/guidelines -gina-report -global -strategy -for-
asthma.html. 2017. 
GlaxoSmithKline Document Number 2015N230821_00 Study  ID 200330. An open -label 
study  of inhaler device attributes investigating critical and overall errors, and ease of use 
and preference between a number of inhaler devices (ELLIPTA, 
DISKUS/ACCUHAL ER, TURBUHALER, and MDI) in adult subjects with asthma 
(Study  200330). Report Date 15 -OCT -2015. 
GlaxoSm ithKline Document Number 2016N269989_01 Study  ID 201594. An open -label 
study  of the ease of use and correct use of placebo ELLIPTA dry  powder inhaler in 
subjects with asthma. Report Date 21 -JUL-2016. 
GlaxoSmithKline Document Number 2017N314003_00 Study  ID204980. An open -label 
study  to evaluate the correct use of placebo ELLIPTA™ dry  powder inhaler (DPI) 
compared to placebo metered dose inhalers (MDI) in subjects with moderate persistent 
asthma. Report Date 31 -JUL-2017. 
Hintze J. PASS Version 12. NCSS, LL C, Kaysville, Utah, USA. 2013. 
Kamps A, Brand P, Roorda R. Determinants of correct inhalation technique in children 
attending a hospital -based asthma clinic. Acta Paediatrica. 2002b;91:159 -63. 
Kamps A, Van Ewijk B, Roorda R, Brand P. Poor inhalation tech nique, even after 
inhalation instruction, in children with asthma. Pediatric Pulmonology. 2000a;29:39 -42. 
Morton R, Everald M, Elphick H. Adherence in childhood asthma: the elephant in the 
room. Archives of Disease in Childhood. 2014;99:949 -53.
NCT0331557 2.Pediatric Ease of Use ELLIPTA Items. RTI Health Solutions and GSK, 
2018. clinicaltrials.gov. 
Nicklas R. Paradoxical bronchospasm associated with the use of inhaled beta agonists. 
Journal of Allergy and Clinical Immunology. 1990;85:959 -64. 
2017N346371_00 CONFI DENTIA L
206924
40Sleath B, Ay ala G, Gillette C, Williams D, Davis S, Tudor G, Yeatts K, Washington D. 
Provider Demonstration and Assessment of Child Device Technique During Pediatric 
Asthma Visits. Pediatrics. 2011;1206:642 -48.
Van der Palen J, Thomas M, Chry styn H, Sharma R, I mber V, Zhu C -Q, Svedsater H. 
Training and Time to Achieve Correct Inhaler Use: A Comparison Between I nhalers in 
Patients with COPD. Am J Respir Crit Care Med. 2016b;193:A6811. 
Van der Palen J, Thomas M, Chry styn H, Sharma R, Van Der Walk P, Goosens M, 
Wilkinson M, Wilkinson T, Stonham C, Chauhan A, I mber V, Zhu C -Q, Svedsater H, 
Barnes N. A randomised open -label cross -over study  of inhaler errors, preference and 
time to achieve correct inhaler use in patients with COPD or asthma: Comparison of 
ELLIPTA with other inhaler devices. NPJ Primary Care Respiratory Medicine. 
2016a;26:16079. 
Van der Palen J, Thomas M. Chry styn H, Sharma R, I mber V, Zhu C -Q, Barnes N. 
Inhaler Preference in Patients with COPD: A Comparison of Ellipta with Five Inhaler 
Devices. Am J Respir Crit Care Med. 2016c;193:A6813. 
2017N346371_00 CONFI DENTIA L
206924
4112. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
AE Adverse Event
CFR Code of Federal Regulation
CI Confidence Interval
CIOMS Council for International Organizations of Medical Sciences
CONSORT Consolidated Standard s of Reporting trials
CSR Clinical Study  Report
DPI Dry Powder Inhaler
EC Ethics Committee
ECG Electrocardiogram 
eCRF Electronic Case Report Form
EW Early Withdrawal
GCP Good Clinical Practice
HCP Healthcare Professional
HIPAA Health Insurance P ortability  and Accountability  Act
IB Investigator Brochure
ICF Informed Consent Form
ICH International Council for Harmonisation of Technical Requirements 
ICS Inhaled Corticosteroids
IEC Independent Ethics Committees
IFU Instructions for Use
IP Investigational Product
IRB Institutional Review Boards
ITT Intent -to-Treat
IWRS Interactive Web Response Sy stem
MDI Metered Dose Inhaler
MITT Modified Intent -to-Treat
LABA Long Acting 2-Agonist
MSDS Material Safet y Da ta Sheet
PIF Peak inspiratory  Flow
RAP Reporting and Anal ysis Plan
SAE Serious Adverse Events 
SoA Schedule of Activities
SRM Study  Reference Manual
SUSAR Suspected Unexpected Serious Adverse Reactions
Trademark Information
Trademarks of the Glaxo SmithKline 
group of companiesTrademarks not owned by the 
GlaxoSmithKline group of companies
ELLIPTA None
2017N346371_00 CONFI DENTIA L
206924
4212.2. Appendix 2: Study  Governance Considerations
Regulatory  and Ethical Considerations
This study  will be conducted in accordance with the protocol and with:
Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines
Applicable International Council for Ha rmonisation of Technical 
Requirements for Pharmaceuticals for Human Use (ICH)Good Clinical 
Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochure, and other 
relevant documents (e .g.advertis ements) must be submitted to an I RB/IEC by  
the investigator and reviewed and approved b y the I RB/IEC before the study  is 
initiated. 
Any amendments to the protocol will require IEC/I RB approval before 
implementation of changes made to the stud y design, exc ept for changes 
necessary  to eliminate an immediate hazard to study  participants. 
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/IEC 
annually  or more frequently  in accordance with the requirements, policies, 
and procedures established by  the IRB/ ethics committee ( EC)
Notify ing the IRB/IEC of SAE or other significant safet y findings as 
required b y IRB/IEC procedures
Providing oversight of the conduct of the stud y at the site and adhe rence to 
requirements of 21 Code of Federal Regulation ( CFR ), ICH guidelines, the 
IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), 
and all other applicable local regulations
Financial Disclosure
Investigators and sub -investigator s will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are respo nsible for providing information on financial interests during the 
course of the stud y and for 1 y ear after completion of the study .
Informed Consent Process
The investigator or his/her representative will explain the nature of the study to 
the participant or his/her legally  authorized representative and answer all 
questions regarding the study . 
2017N346371_00 CONFI DENTIA L
206924
43Participants must be informed that their participation is voluntary . Participants 
or their legall y authorized representative will be required to sign a statement o f 
informed consent that meets the requirements of 21 CFR 50, local regulations, 
ICH guidelines, Health Insurance Portability  and Accountability  Act (HI PAA) 
requirements, where applicable , and the IRB/IEC or study  cent re. 
The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent 
must also sign the I CF.
Participants must be re -consen ted to the most current version of the ICF(s) 
during their participation in the study . 
A cop y of the ICF(s) must be provided to the participant or the participant’s 
legally  authorized representative. 
Participants who are rescreened are required to sign a new ICF.
Signed assent will be obtained where considered appropriate according to the 
subject’s age and comprehension, as determined by  the Investigator.
Data Protection
Participants will be assigned a unique identifier by  the sponsor. Any  participant 
records or datasets that are transferred to the sponsor will contain the identifier 
only; participant names or any  information which would make the participant 
identifiable will not be transferred. 
The participant must be informed that his/her personal study -related data will be 
used by  the sponsor in accordance with local data protection law. The level of 
disclosure must also be explained to the participant. 
The participant must be informed that his/her medical records may  be examined 
by Clinical Qualit y Assurance auditors or other authorized personnel appointed 
by the sponsor, b y appropriate IRB/IEC members, and by  inspectors from 
regulatory  authorities.
Committees Structure
Not Applicable
Publication Policy
The results of this study  may  be published or pre sented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to 
the sponsor before submission. This allows the sponsor to protect proprietary  
information and to provide comments.
The sponsor will compl y with the requirements for publication of study  results. 
In accordance with standard editorial and ethical practice, the sponsor will 
generall y support publication of multi center studies only  in their entiret y and 
2017N346371_00 CONFI DENTIA L
206924
44not as individual site data. I n this cas e, a coordinating investigator will be 
designated b y mutual agreement.
Authorship will be determined by  mutual agreement and in line with 
International Committee of Medical Journal Editors authorship requirements.
Dissemination of Clinical Study  Data
Where required b y applicable regulatory  requirements, an investigator signatory  
will be identified for the approval of the clinical study  report.  The investigator 
will be provided reasonable access to statistical tables, figures, and relevant 
reports and will have the opportunity  to review the complete study  results at a 
GSK site or other mutually -agreeable location.
GSK will also provide the investigator with the full summary  of the stud y 
results.  The investigator is encouraged to share the summary  results wi th the 
study  subjects, as appropriate.
GSK will provide the investigator with the randomization codes for their site 
only after completion of the full statistical anal ysis.
The procedures and timing for public disclosure of the results summary  and for 
deve lopment of a manuscript for publication will be in accordance with GSK 
Policy .
A manuscript will be progressed for publication in the scientific literature if the 
results provide important scientific or medical knowledge.
Data Quality  Assurance
All partici pant data relating to the stud y will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically  (e.g. laboratory  
data). The investigator is responsible for verify ing that data entries are accurate 
and correct b y physicall y or electronically signing the eCRF. 
The investigator must maintain accurate documentation (source data) that 
supports the information entered in the eCRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regula tory agency  inspections and provide direct access to source data 
documents. 
The sponsor or designee is responsible for the data management of this study  
including qualit y checking of the data. 
Study  monitors will perform ongoing source data verification to confirm that 
data entered into the eCRF b y authorized site personnel are accurate, complete, 
and verifiable from source documents; that the safety  and rights of participants 
are being protected; and that the study  is being conducted in accordance with t he 
currentl y approved protocol and an y other stud y agreements, ICH GCP, and all 
applicable regulatory  requirements. 
Records and documents, including signed ICF, pertaining to the conduct of this 
study  must be retained by  the investigator for 25 y ears from the issue of the final 
2017N346371_00 CONFI DENTIA L
206924
45Clinical Study  Report (CSR)/ equivalent summary unless local regulations or 
institutional policies require a longer retention period. No records may  be 
destroy ed during the retention period without the written approval of the 
sponso r. No records may be transferred to another location or part y without 
written notification to the sponsor. 
Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
Data entered in the eCRF that are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained. 
The investigator may  need to request previous medical records or transfer 
records, depending on the study . Also, current medical records must be 
available.
Definition of what constitutes source data can be found in the source data 
agreement or source data verification form.
Study and Site Closure
GSK or its d esignee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of GSK. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons fo r the earl y closure of a stud y site b y the sponsor or investigator may include 
but are not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the I RB/IEC 
or local health authorities, the sponsor's procedures, or GCP gu idelines
Inadequate recruitment of participants by the investigator
Discontinuation of further study  treatment development
2017N346371_00 CONFI DENTIA L
206924
4612.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
Definition of A E
AE Defini tion
An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of a study  treatment, whether or not considered related to the 
study  treatment.
NOTE: An AE can therefore be an y unfavorable and unintended s ign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study  treatment.
Events Meeting the AE Definition 
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) or 
other safet y assessments (e .g.ECG [electrocardiogram] , radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator (i .e.not related to 
progression of underly ing disease).
Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment administration even though it 
may have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment o r a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae.
The signs, s ymptoms, and/or clini cal sequelae resulting from lack of efficacy will be 
reported as AE or SAE if they  fulfill the definition of an AE or SAE. Also, "lack of 
efficacy " or "failure of expected pharmacological action" constitutes an AE or SAE.
Events NOT Meeting the AE Defini tion 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The dis ease/disorder being studied or expected progression, signs, or s ymptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.
2017N346371_00 CONFI DENTIA L
206924
47Medical or surgical procedure (e .g.endoscopy , appendectom y): the condition tha t leads 
to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
Definition of SA E
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e .g.hospitalization for signs/sy mptoms of the disease under study , 
death due to prog ression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death a t the time of the event. I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the par ticipant has been detained (usually  
involving at least an overnight stay ) at the hospital or emergency  ward for observation 
and/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur duri ng hospitalization are AE. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred, or was necessary , the 
AE should be considered serious.
Hospitalizati on for elective treatment of a pre -existing condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct normal 
life fu nctions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea , influenza, and 
accidental trauma (e .g.sprained ankle) which may  interfere with or prevent every day life 
functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
2017N346371_00 CONFI DENTIA L
206924
48appropriate in other situations such as important medical events that may  not be 
immediately  life-threatening or result in death or hospitalization but may  jeopardize the 
participant or may  require medical or surgical intervention to prevent one of the other 
outcomes listed in the above definit ion. These events should usually  be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hosp italization, or development of drug dependency 
or drug abuse.
Recording A E and SA E
AE and SAE Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e .g.hospital progress notes, laboratory , and diagno stics reports) related 
to the event.
The investigator will then record all relevant AE/SAE information in the eCRF.
It is notacceptable for the investigator to send photocopies of the participant’s medical 
records to GSK in lieu of completion of the GSK / AE/SAE eCRF page.
There may  be instances when copies of medical records for certain cases are requested by  
GSK. I n this case, all participant identifiers, with the exception of the participant number, 
will be redacted on the copies of the medical records b efore submission to GSK.
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  the participant, causing minimal disc omfort and 
not interfering with every day activities.
Moderate: An event that causes sufficiently  discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities. An AE that is assessed as 
severe should n ot be confused with an SAE. Severe is a category  utilized for rating the 
intensity  of an event; and both AE and SAE can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definiti on of an SAE, NOT when it is rated as severe.
2017N346371_00 CONFI DENTIA L
206924
49Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment and each 
occurrence of each AE/SAE.
A "reasonable possibility " of a relationship conveys that there a re facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other risk 
factors, as well as the temporal relationship of the event to study  treatment administration 
will be considered and investigated.
The investigator will also consult the I nvestigator’s Brochure (IB) and/or Product 
Information, for m arketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There may  be situations in which an SAE has occurred and the inve stigator has minimal 
information to include in the initial report to GSK. However, it is very important that 
the investigator always make an assessment of causality for every event before the 
initial transmission of the SAE data to GSK .
The investigator ma y change his/her opinion of causality  in light of follow -up 
information and send an SAE follow -up report with the updated causality  assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follo w-up of AE and SAE
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  GSK to 
elucidate the nature and/or causalit y of the AE or SAE as fully as poss ible. This may  
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
If a participant dies during participation in the study or during a recognized follow -up 
period, the investigator will provide GSK with a copy  of any  post -mortem findings 
including histopathology .
New or updated information will be recorded in the originally  completed eCRF.
The investigator will submit any  updated SAE data to GSK within 24 hours of recei pt of 
the information.
Reporting of SA E to GSK
SAE Reporting to GSK via Electronic Data Collection Tool
The primary  mechanism for reporting SAE to GSK will be the electronic data collection 
2017N346371_00 CONFI DENTIA L
206924
50tool.
If the electronic s ystem is unavailable, then the site wi ll use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
The investigator or medically -qualified sub -investigator must show evidence within the 
eCRF (e.g., check review box, signature, etc.) of review and verification of the 
relationship of each SAE to I P/study  participation (causalit y) within 72 hours of SAE 
entry  into the eCRF.
After the stud y is completed at a giv en site, the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated data 
on a previousl y reported SAE after the electronic data collection tool has been taken off -
line, then the site can report this information on a paper SAE form (see next section) or to 
the medical monitor by  telephone.
Contacts for SAE reporting can be found in the SRM.
2017N346371_00 CONFI DENTIA L
206924
5112.4. Appendix 4: Country -specific requirements
N/A
2017N346371_00 CONFI DENTIA L
206924
5212.5. Appendix 5: ELLIPTA  DPI correct use and critical error 
checklist
12.5.1. Checklist
The Checklist for correct use of the ELLIPTA DPI, based on the steps identified in the 
IFUare included in the table below. This will be filled out by  the HCP during the 
demonstration by  the participant. Following removal of the inhaler from the packaging, 
an eligible stud y participant will be guided per the instructions in the (Schedule of 
Activities (SoA) (Section 2))to demo nstrate correct use of the ELLIPTA DPI . The steps 
outlined in these instructions require that actions be checked b y an E LLIPTA trained 
HCP at both Visit 1 (up to 3 attempts with HCP and 2 further attempts with HCP and 
parent/guardian ) and at Visit 2 (1 att empt with no training or instruction and then 1 
attempt after instruction from parent/guardian) .
Theformatting or lay out may  change prior to use by  the site . Furthermore, the IFU 
wording may  alter depending the country  involved in the study . However, the specific 
definition of correct use outlined in these checklists will not change.
Critical errors are indicated by  the steps that are underlined in the checklists.  
Protocol Identifier
206924Subject Identifier ELLIPTA  DPI correct 
use/critical erro rchecklist
Visit #
Date of A ssessment:
DAY MONTH YEAR
IFU  
StepIFUWording (2017) Correct use (Critical errors 
denoted by underlined steps)YES NO
1 Open the cover of the inhaler
• Slide the cover down to expose the 
mouthpiece. You sho uld hear a “c lick”.
You do not need to shake this kind of 
inhaler.
Your inhaler is now ready to use
•If the counter does not count down as 
you hear the click, the inhaler will not 
deliver the medicine. Call your 
healthcare provider or pharmacist if this 
happens.Participant slides the cover 
completely down to expose the 
mouthpiece until a “click” is heard.
Participant does not shake the 
inhaler 
(Note: a “Yes” response indicates 
that the participant did not shake 
the inhaler after the click is heard)
2017N346371_00 CONFI DENTIA L
206924
53IFU  
StepIFUWording (2017) Correct use (Critical errors 
denoted by underlined steps)YES NO
2 Breathe out
• While holding the inhaler away from 
your mouth, breathe out (exhale) fully .• 
• Do not breathe out into the 
mouthpiece .Participant breathes out (exhales) 
while hold ing the inhaler away from 
their mouth.
Participant does not breathe into 
the mouthpiece . 
(Note: a “Yes” response indicates 
that the participant did not breathe 
into the mouthpiece)
3 Inhale your medicine
• Put the mouthpiece between your 
lips, and close your lips firmly around it.
Your lips should fit over the curved 
shape of the mouthpiece
• Take one long, steady, deep breath in
through your mouth . Do not breathe in 
through yo ur nose
• Do not block the air vent with your 
fingers.
• Remove the inhaler from your 
mouth and hold your breath for 
about 3 to 4 seconds (or as long as is 
comfortable for you).Participant places mouthpiece 
between lips, and closes lips firmly 
around it.
Participant takes one long steady 
deep breath in through their mouth.
Participant does not block air vent 
with fingers.
(Note: a “Yes” response indicates 
that the participant did not block 
the air vent with their fingers)
Participant removes inhaler from 
his/her mouth and holds his/her 
breath.
4 Breathe out slowly and gently.
•You may not taste or feel the 
medicine, even when you are using the 
inhaler correctly
•Do not take another dose from the 
inhaler even if you do not feel or taste 
the medicineParticipant breathes out slowly and 
gently.
5 Close the inhal er 
•You can clean the mouthpiece if 
needed, using a dry tissue, before you 
close the cover. Routine cleaning is not 
required.
• Slide the cover upwards as far as it 
will go to cover the mouthpiece.Participant closes the inhaler 
completely.
6 Rinse your mouth
•Rinse your mouth with water after you 
have used the inhaler and spit the 
water out. Do not swallow the water.
2017N346371_00 CONFI DENTIA L
206924
5412.6. Appendix 6: Ease of use Questionnaire(s)
Paper copies of the ease of use questions will be used by the administrator (Investigator 
or designee) to record participants’ answers to the questions. The site will enter the 
answers into the electronic case report form (eCRF). 
INSTRUCTIONS: The administrator (Investigator or designee) will complete the 
following questions related to the ELLIPTA inhalers used during this study. 
Check only one response for the question asked. 
Survey  questions VERSION “A” OR “B” to be completed at Visit 2 as per 
randomization at Visit 2.
12.6.1. Ease of use Questionnaire (Participan t Stratum 1, ages 5 -7 years)
Instructions: “ I am going to ask you some questions about using this inhaler [interviewer 
has placebo ELLIPTA DPI]. The name of the inhaler is ELLIPTA. I will read the 
question and answers to you. Then I will ask you to choose the answer that matches what 
you thought about using the ELLIPTA at home. Do you have any questions for me? ” 
12.6.1.1. Version A
1)Is it easy or hard to use the ELLIPTA inhaler?
□ Eas y 
□ Hard   
2)Is it easy or hard is it to tell how many  puffs are left in the ELLIPTA inhaler?
□ Eas y 
□ Hard    
12.6.1.2. Version B
1)Is it hard or eas yto use the ELLIPTA inhaler?
□ Hard
□ Easy   
2)Is ithard or eas yis it to tell how many  puffs are left in the ELLIPTA inhaler?
□ Hard 
□ Eas y   
12.6.2. Ease of use Questionnaire (Participant Stratum 2, ages 8 -11 
years)
Instructions: “I am going to give you a paper with three questions about the inhaler you 
used during the study  [interviewer has placebo ELLIPTA DPI]. The name of the inhaler 
is ELLIPTA. Read the questions and choose the answer that best matches what you 
2017N346371_00 CONFI DENTIA L
206924
55thought about using the ELLIPTA at home. Do you have any questions? ” [Pause and 
answer an y questions from participant. If participant needs help in understa nding the 
questions or responses, you can explain or define individual words but please take care 
not to influence his or her answer].
For participants that have difficulty  completing the self -administered version, they  may  
receive the questionnaire in th e same manner as is provided for stratum 1.
12.6.2.1. Version A
1)Is iteasy or hard to use the ELLIPTA inhaler?
□ Eas y 
□ Hard    
2)Is iteasy or hard is it to tell how many  puffs are left in the ELLIPTA inhaler?
□ Eas y 
□ Hard    
12.6.2.2. Version B
1)Is it hard or eas y to use th e ELLIPTA inhaler?
□ Hard
□ Easy   
2)Is it hard or eas yto tell how many  puffs are left in the ELLIPTA inhaler?
□ Hard 
□ Eas y   
12.6.3. Ease of use Questionnaire (Parent/Guardian)
Parents/Guardians will be assigned to the same version letter (A or B) to which th eir 
child/dependent was randomized.
12.6.3.1. Version A
1)How eas y or difficult was it for you to tell how many doses were left in the ELLIPTA 
inhaler ?
□ Very  Easy
□ Easy
□ Difficult
□ Very  Difficult
2)If your child’s current inhaled asthma medication was available in the ELLIPTA 
inhaler, how likel y would you be to request the ELLIPTA inhaler from y our child’s 
doctor ?
2017N346371_00 CONFI DENTIA L
206924
56□ Very  Likely
□ Likely
□ Unlikely
□ Very  Unlikely
12.6.3.2. Version B
1)How difficult or eas ywas it for y ou to tell how many  doses were left in the ELLIPTA 
inhaler?
□ Very  Difficult
□ Difficult
□ Eas y 
□ Very  Easy
2)If your child’s current inhaled asthma medication was available in the ELLIPTA 
inhaler, how likel y would you be to request the ELLIPTA inhaler from y our child’s 
doctor ?
□ Very  Unlikely
□ Unlikely
□ Likely
□ Very  Likely
2017N346371_00 CONFI DENTIA L
206924
5712.7. Appendix 7: Protocol A mendment History
N/A